BAJAJ FINSERV DIRECT LIMITED
Open Your FREE Demat Account Now!

Natco Pharma Ltd. Share Price

NSE
BSE

NSE : NATCOPHARM

BSE : 524816

Sector : Healthcare

N/A
indicator
1D
1M
3M
6M
1Y
5Y
empty graph

Day's Range

Day's Range

Low

₹924.00

High

₹968.90

Price Summary

Previous Close ₹968.00
Day's Range ₹924.00 - ₹968.90
Open ₹934.90
52 Week Range ₹789.00 - ₹1,226.80
Volume 7,22,753
Market Cap ₹0.02
Previous Close ₹964.85
Day's Range ₹924.65 - ₹968.65
Open ₹932.10
52 Week Range ₹789.30 - ₹1,226.10
Volume 34,515
Market Cap ₹0.02

Stocks Summary

Trade Value ( ₹ in Lacs) 6,996.25
Market Cap (₹ in Mn) 0.02
Dividend Yield(%) 0.54
Price/Earning (TTM) 11.76
TTM EPS (₹) 79.20
P/E Ratio 7.57
Book Value(₹) 1.81
PAT Margin (%) 39.54
Face Value (₹) 2.00
ROCE(%) 32.85
Trade Value ( ₹ in Lacs) 333.02
Market Cap (₹ in Mn) 0.02
Dividend Yield(%) 0.54
Price/Earning (TTM) 11.76
TTM EPS (₹) 79.20
P/E Ratio 7.57
Book Value(₹) 1.81
PAT Margin (%) 39.54
Face Value (₹) 2.00
ROCE(%) 32.85

Financials

Particulars QTR FY (₹ in Millions) Annual FY (₹ in Millions)
Net sales 44295.0 12210.0
Expenses N/A N/A
PBT 22914.0 5059.0
Operating profit 0.0 0.0
Net profit 18834.0 4060.0

Shareholding Pattern

Promoters (% Holding)

49.42%

Mutual funds (% Holding)

1.72%

Non-Institution (% Holding)

27.76%

FI/Banks/Insurance (% Holding)

3.30%

Government (% Holding)

0.00%

FII

17.37%

About Natco Pharma Ltd.

Founded 1981
Managing Director V C Nannapaneni
NSE Symbol NATCOPHARM

Peer Comparision

Stocks Name Market Cap (Cr)(₹) Market Price (₹) 52 Week Low-High (₹)
Sun Pharmaceutical Industries Ltd. 4,59,004.78 1,913.10 1,548.00 - 1,548.00
Divi's Laboratories Ltd. 1,81,867.21 6,819.50 5,636.50 - 5,636.50
Torrent Pharmaceuticals Ltd. 1,63,245.77 4,859.05 3,295.30 - 3,295.30
Apollo Hospitals Enterprise Ltd. 1,27,857.63 8,856.00 6,696.50 - 6,696.50
Cipla Ltd. 1,18,854.24 1,466.05 1,165.70 - 1,165.70
Zydus Lifesciences Ltd. 1,14,518.43 1,161.95 835.50 - 835.50
Dr. Reddy's Laboratories Ltd. 1,14,246.25 1,367.70 1,148.40 - 1,148.40
Lupin Ltd. 1,13,962.92 2,495.00 1,836.80 - 1,836.80
Max Healthcare Institute Ltd. 1,10,229.59 1,136.05 903.00 - 903.00
Mankind Pharma Ltd. 1,04,911.30 2,536.60 1,909.70 - 1,909.70
no-content No Records Found

Latest News

Jun
3
2026
EQUITY Posted on Jun 3rd 2026

Natco Pharma informs about press release

Natco Pharma has informed that it enclosed press release titled ‘NATCO Pharma Limited and Lupin Limited receive approval from U.S. FDA for Eribulin Mesylate Injection’.
The above information is a part of company’s filings submitted to BSE.
Read More
Jul
6
2026
EQUITY Posted on Jul 6th 2026

Aster DM Healthcare informs about disclosure

Aster DM Healthcare has informed that the exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for BCP Asia II Topco IV.
The above information is a part of company’s filings submitted to BSE.
Read More
Jul
6
2026
EQUITY Posted on Jul 6th 2026

Sai Parenterals informs about outcome of board meeting

Sai Parenterals has informed that the Board Meeting of Sai Parenterals held on Monday, the 06th day of July, 2026 at 11:30 AM at the Registered Office of the Company considered and approved the following: Appointment of Aakanksha Dubey & Co., Practicing Company Secretaries as Secretarial Auditors of the Company for a period of Five (5) Financial Years from 2026-27 to 2030-31. (Details are attached as Annexure A); Appointment of NSVR & Associates LLP, Chartered Accountants, as Internal Auditors of the Company for the FY 2026-27. (Details are attached as Annexure A); Appointment of Sai Krishna & Associates, Cost Auditors, as Cost Auditors of the Company for the FY 2026-27. (Details are attached as Annexure A); Authorisation to  Anil Kumar Karusala, Chairman & Managing Director of the Company to identify, evaluate and explore suitable organic and inorganic growth opportunities in the existing line of business or in such other strategic areas as may be beneficial to the Company. The Meeting of the Board concluded at 03:10 pm.
The above information is a part of company’s filings submitted to BSE.
Read More
Jul
6
2026
EQUITY Posted on Jul 6th 2026

Corona Remedies informs about compliances-certificate

Pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, as amended from time to time, Corona Remedies has enclosed a copy of the certificate received from Bigshare Services, Registrar to Issue and Share Transfer Agent of the Company, for the first quarter ended on June 30, 2026.
The above information is a part of company's filings submitted to BSE.
Read More
Jul
6
2026
EQUITY Posted on Jul 6th 2026

Blue Jet Healthcare informs about resignation of statutory auditors

Blue Jet Healthcare has informed that the Board of Directors of Blue Jet Healthcare at its meeting held on May 25, 2026, has approved the audited standalone financial statements of the Company for the financial year ended March 31, 2026, together with the notes and schedules thereto and the audit report thereon, including the comparative figures for the financial year ended March 31, 2025, prepared in accordance with the applicable provisions of the Companies Act, 2013 and the applicable accounting standards. A copy of the audited standalone financial statements together with the notes and schedules thereto along with the audit report thereon is enclosed. The audited standalone financial statements of the Company for the financial year ended March 31, 2026, together with the notes and schedules thereto and the audit report thereon, are subject to adoption by the shareholders of the Company at the ensuing Annual General Meeting. The above intimation will also be available on the website of the Company, www.bluejethealthcare.com.
The above information is a part of company's filings submitted to BSE.
Read More
no-content No Records Found

Sign in to Unlock Offers!

Explore Loans, Cards, Investments & Insurance

No SPAM We don't SPAM
Right Hand Side Image
STEP 1/2

Open Demat Account today!

+91

Enter mobile number

Invalid mobile number

Enter Full Name

Invalid Full Name

Verification required
close

Enter the One Time Password (OTP)

Sent to ********99

Edit Number
Enter valid OTP
Field should not be blank
You have exhausted your OTP attempts try again after 10 min

Request another in 60s

Resend OTP

secure   100% safe and secure

Frequently Asked Questions

What is the current share price of Natco Pharma Ltd. ?

The current share price of Natco Pharma Ltd. is ₹968.00 as of 2026-07-07.

The market capitalisation of Natco Pharma Ltd. is ₹16,687.67 as of 2026-07-06.

The 1-year return of Natco Pharma Ltd. is -30.60% as of 2026-07-07.

The P/E ratio of Natco Pharma Ltd. is 7.57 as of 2026-07-07.

The 52-week high and low of Natco Pharma Ltd. are ₹1,226.80 and ₹789.00, respectively, as of 2026-07-07.

The dividend yield of Natco Pharma Ltd. is 0.5367% as of2026-07-06.

You can buy Natco Pharma Ltd. shares through a registered stockbroker or trading platform. Bajaj Markets partners with trusted brokers to help you open a demat account. This is the first step to trading, making it easier to invest in your desired shares.

The Managing Director of Natco Pharma Ltd. is V C Nannapaneni.

When investing in a company’s stock, you may consider key factors such as its fundamentals, including financial health, historical performance, and growth potential. Assess the consistency of its performance, market conditions, and industry trends. Additionally, evaluate your own risk tolerance while reviewing aspects like quarterly earnings, management quality, and sector performance, for taking a well-informed decision.

You can track stock performance on online platforms through live market updates, historical charts, and news alerts. Regular analysis and stock alerts allow you to stay informed about significant price changes and events affecting the stock.

Common stock provides voting rights and the potential for dividends based on company performance, while in case of preferred stock, stockholders receive fixed dividends and have priority over common stockholders in asset distribution but generally lack voting rights.

Stock investments carry market risks, including price volatility, economic shifts, and sector-specific issues. Managing risk can involve diversifying your portfolio, setting stop-loss orders, and staying informed about market trends to make timely decisions.

Market capitalisation, or market cap, is the total value of a company’s outstanding shares and is calculated by multiplying the stock price by the total shares. It classifies companies as large-cap, mid-cap, or small-cap, reflecting their size, stability, and potential risk level in the stock market.

View More

People Also Ask

What healthcare products are offered by Natco Pharma Ltd.?

Natco develops generic and specialty drugs, with strong positions in oncology, cardiology, gastro, and CNS, plus agro‑chemicals through its crop‑health division.

Natco collaborates on licensing, contract manufacturing, and supplies hospital‑focused oncology generics and complex formulations in India and export markets.

Natco Pharma is an Indian pharmaceutical company that researches, develops, manufactures, and markets generic medicines, oncology‑focused products, active pharmaceutical ingredients (APIs), and agro‑health solutions for domestic and international markets.

NATCO is the brand and corporate name used by Natco Pharma Limited. The company does not prominently use or disclose an official expanded form of the abbreviation in its public corporate identity.

Before it became Natco Pharma Limited, the company was initially known as Natco Fine Pharmaceuticals, under which it started its operations in thepharmaceutical sector.

Among the products introduced by Natco Pharma in recent years is Pomalidomide Capsules, a generic version of the cancer drug Pomalyst, introduced in the U.S. for treating multiple myeloma.

The head office and registered office of Natco Pharma India is located in Hyderabad, Telangana, from where it manages its pharmaceutical and agro‑health operations for Indian and global markets.

Natco Pharma is famous for producing affordable generic and oncology medicines, including pioneering compulsory‑license versions of high‑cost cancer drugs that have significantly improved access to life‑saving treatments.

View More

Disclaimer

All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.

The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.

Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform. 

Invalid Mobile Number

Invalid Full Name

Home
Home
ONDC_Shopping
Shopping
Loan
Loan Offers
My Accounts
My Accounts
Explore
Explore